Top

Cannvas Launching Cannabis-Focused Health Care Platform for Animals with Cannvas.PET

Cannvas Launching Cannabis-Focused Health Care Platform for Animals with Cannvas.PET

Healthcare Through Cannabis for the Family Pet

TORONTO, Sept. 13, 2018 /CNW/ – Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE: MTEC, Frankfurt: 3CM), a leading business technology company in the cannabis space, is pleased to introduce its second cannabis-centric educational platform, aimed at healthcare and wellness through cannabis for furry family friends. Built on the same infrastructure as Cannvas.Me, Cannvas.PET will be a scalable and comprehensive solution for the global pet community offering interactive tools and research-backed content to audiences who wish to learn about pet healthcare through cannabis.

“As pet owners search for natural alternatives to improve the health of their pet, more and more are looking to medical cannabis only to find a lack of quality information,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “We are leveraging our existing infrastructure to launch an online educational portal targeted at the large and growing market for cannabis pet products. Cannvas.PET will be a leading source of alternative healthcare for all manner of pets, providing owners with information and education regarding the various treatments available. While supporting a healthy and happy lifestyle for pets, it will stand independent from licensed producers and other entities to ensure unbiased information is free from outside influences.”

Similar to the Cannvas.Me education platform, Cannvas.PET will be a free-to-use online platform using machine-learning algorithms and artificial intelligence to contextualize and adapt to users of the platform, ensuring the content they are served remains geographically and personally relevant to them. The site will feature innovative tools such as educational learning modules and an interactive service to educate pet owners with specific concerns about the different strains available.

With the legalization of cannabis on October 17, 2018 Canadian pet owners will have the opportunity to use medical-grade cannabis for the health care of their pets. Similar to the human medical cannabis marketplace, high-quality non-combustible cannabis products can be a natural alternative in supporting the overall health and well-being of pets. Pets suffer just like humans and with the growing demand for alternative treatments there is a need for a trusted source of medical cannabis treatments to help with pet-related ailments. Research on CBD treats and oils has shown promise in many pet ailments like phobias, digestive problems inflammation and pain.

In Canada, there are approximately 16 million cats and dogs with almost two-thirds of households owning a pet. Pet owners are increasingly treating pets as an extension of their family, driving annual pet-related expenditures to in excess of $5 billion in Canada and almost US$70 billion in the United States.

With over 350 million pets globally, there is a sizeable market opportunity for cannabis products and supporting technologies like the scalable Cannvas.PET educational platform.

 

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

SOURCE Cannvas MedTech Inc.

For further information: www.cannvasmedtech.com, Media Inquiries: media@cannvasmedtech.com, Investor Relations: ir@cannvasmedtech.com, 1-800-489-0116

X